Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
GRACE and Clinical Care Options Online Patient Tool for Ovarian Cancer
dbrock
Treatment Options From 5 Experts for Advanced Ovarian Cancer: An Online Tool for Patients
Image
Have you received a diagnosis of ovarian cancer?
GRACE is excited to have again partnered with Clinical Care Options to develop an Interactive Decision Support Tool and downloadable resource to help you understand more about your disease and treatment options, so you can become partners with your oncology team in your cancer care.
By answering multiple choice questions about your diagnosis, you will be able to review treatment options from five ovarian cancer experts listed below.
-
Robert L. Coleman, MD, FACOG, FACS Texas Oncology
- Thomas J. Herzog, MD UC Health
- Ursula Matulonis, MD Dana Farber/Harvard Cancer Center
- Bradley J. Monk, MD, FACOG, FACS Arizona Oncology
- Kathleen Moore, MD Stephenson Cancer Center
Clinical Care Options LLC, is a global leader in the development of innovative educational programs and technology platforms. GRACE is pleased to work with CCO on a number of patient materials and tools to help our community in their cancer journey.
The following list of decision support tools are available on our GRACE and Clinical Care Options Patient Tools partner page:
-
Treatment Options From 5 Experts for Patients With Ovarian Cancer
-
Expert Insights Interactive Decision Support Tool for Advanced NSCLC
-
Information Regarding Immune Checkpoint Inhibitor Therapy
-
Educational Video - Immunotherapy for Advanced NSCLC: Discussing Goals and Treatments With Your Health Care Provider
-
Expert Insights Interactive Decision Support Tool on HER2+ Early Stage Breast Cancer
-
Expert Insights Interactive Decision Support Tool on Melanoma
-
Expert Insights Interactive Decision Support Tool for Frontline Follicular Lymphoma
-
Educational Videos -Measurable Residual Disease (MRD) in Acute Lymphocytic Leukemia (ALL)
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial. We want to hear from you!
Image
Video
The Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón presentado el 9 de agosto de 2025 has now ended.
¡Los vídeos están disponibles BAJO DEMANDA!
Las versiones completas sin editar del Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón de agosto de 2025 ya están disponibles BAJO DEMANDA. Estos temas se editarán y se ofrecerán en forma de vídeos más cortos en las próximas semanas.
Image
Article
Da click aquí para más información y para registrarte ahora
Online Community
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.